If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...

Hikma Pharmaceuticals’ latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts broadly maintain a constructive view on its long term growth ...